tbuckley/cabot-search huggingface dataset:
Abstract 15303: The Impact of Heart Rate on the Incidence of Cardiovascular Events in Patients With Chronic Atrial Fibrillation: The Fushimi Af Registry
Authors: Moritake Iguchi, Hisashi Ogawa, Hirofumi Sugiyama, Nobutoyo Masunaga, Mitsuru Ishii, Masahiro Esato, Yeong-Hwa Chun, Hiromichi Wada, Koji Hasegawa, Mitsuru Abe, Masaharu Akao
Journal: Circulation (2015)

Purpose: Previous reports suggested that lenient rate control was not inferior to strict rate control among patients with chronic atrial fibrillation (AF). However, the impact of heart rate (HR) on the incidence of cardiovascular events is not clearly understood. Methods: The Fushimi AF Registry, a community-based prospective survey, was designed to enroll all of the AF patients in Fushimi-ku, Kyoto, Japan. At present, follow-up data were available in 3,514 patients (median follow-up period, 842 days). 1,622 patients had chronic AF, and we obtained ECG findings in 1,561 patients. We divided these patients into three groups based on their heart rate; high-HR (HR≥110) (n=179), intermediate-HR (80≤HR&lt;110) (n=695), and low-HR (HR&lt;80) (n=687), and explored the cardiovascular events (composite of cardiovascular death, hospitalization for heart failure, and arrhythmic events). Results: Mean HR was 128±13 bpm, 93±8 bpm, and 67±9 bpm, respectively. High HR group was younger than other groups, but the prevalence of heart failure was the highest (44.7%, 37.0%, 32.3%; p=0.007) and left-ventricular ejection fraction was the lowest (56.5±14.6%, 60.7±11.9%, 62.7±10.5%; p&lt;0.0001). Prescription of beta-blocker (37.4%, 28.9%, 30.0%) and diltiazem (2.8%, 2.9%, 4.2%) was comparable, but prescription of verapamil was the highest in high-HR group (19.0%, 12.4%, 8.0%; p=0.0001), and prescription of digitalis was the highest in low-HR group (14.0%, 18.2%, 23.4%; p=0.005). Mean CHADS2 score was 2.3±1.3, 2.2±1.3, and 2.2±1.4, respectively. In Kaplan-Meier analysis, the incidence of cardiovascular events was higher in high-HR groups than intermediate- and low-HR group (9.2%/year vs 5.8%/year, p=0.02), but was similar between intermediate- and low-HR group (6.2%/year vs 5.4%/year, p=0.3). The incidence of stroke or systemic embolism was comparable between the three groups (2.6%/year, 3.6%/year, 2.4%/year). Cox proportional hazard ratios [95%CI] of high- and intermediate-HR for cardiovascular events compared to low-HR were 1.63 [1.06-2.44] and 1.10 [0.81-1.79], respectively. Conclusions: Among chronic AF patients, the incidence of cardiovascular events was higher in the patients with high-HR, but was similar between intermediate- and low-HR groups.
ATCT-03RETROSPECTIVE REVIEW OF GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB-CONTAINING AND NON-BEVACIZUMAB-CONTAINING REGIMENS IN A SINGLE INSTITUTION
Authors: Yoshiki Arakawa, Takashi Mizowaki, Masahiro Tanji, Yohei Mineharu, Kengo Ogura, Megumi Uto, Takeharu Kunieda, Yasushi Takagi, Susumu Miyamoto
Journal: Neuro-Oncology (2015)

OBJECTIVE: Bevacizumab has been reported not to improve survival in patients with glioblastoma in addition to radiotherapy-temozolomide. The Japanese Ministry of Health, Labour and Welfare has approved BEV for newly-diagnosed and recurrent malignant glioma on June 14, 2013. Therefore, we analyze retrospectively clinical outcomes of glioblastoma patients treated with bevacizumab-containing and non-bevacizumab-containing regimens in our institution. SUBJECTS AND METHODS: Between 2006 and 2013, 94 patients with newly-diagnosed glioblastoma were treated with radiotherapy with concomitant and adjuvant temozolomide. To patients with tumor progression, we applied ICE (ifosfamide, carboplatin, and etoposide), CPT-11, etoposide, bevacizumab and bevacizumab-containing regimen with temozolomide, ICE, and CPT-11. RESULTS: 43 patients have been treated with bevacizumab-containing regimens (bevacizumab group) and 51 patients with non-bevacizumab-containing regimens (non-bevacizumab group). Median survival times in bevacizumab group and non-bevacizumab group were 21.7 and 17.2 months, respectively (p = 0.45). Recurrences were identified in 41 patients of bevacizumab group and 38 patients of non-bevacizumab group. In analysis of patients with recurrent glioblastoma, median survival time in bevacizumab group (21.7 months) was significantly longer than in non-bevacizumab group (14.2 months) (p = 0.031). CONCLUSION: Bevacizumab-containing regimens showed significant survival benefit in the patients with recurrence of glioblastoma and temozolomide failure, compared with non-bevacizumab-containing regimens.
Endoscopic submucosal dissection for early rectal neoplasia: experience from a European center
Authors: Andreas Probst, Alanna Ebigbo, Bruno Märkl, Tina Schaller, Matthias Anthuber, Carola Fleischmann, Helmut Messmann
Journal: Endoscopy (2016)

<b>Background and study aims</b> Endoscopic resection is a curative treatment option for large nonpedunculated colorectal polyps (LNPCPs). Endoscopic submucosal dissection (ESD) allows en bloc resection but ESD experience is still limited outside Asia. The aim of our study was to evaluate the role of ESD in the treatment of early rectal neoplasia in a European center. <b>Patients and methods</b> 330 patients referred for endoscopic resection of rectal LNPCPs were included prospectively. <b>Results</b> ESD was performed for 302 LNPCPs (median diameter 40 mm). Submucosal invasive cancer (SMIC) was present in 17.2 % (n = 52). SMIC was associated with Paris type (54.5 % among type 0-Is lesions, 100 % of 0-Is-IIc type, 0 % of 0-IIa, 14.9 % of 0-IIa-Is, and 59.3 % of 0-IIa-IIc type; <i>P</i> < 0.001) and with surface pattern (71.4 % among nongranular plus mixed surface lesions, 17.9 % of lesions with granular surface and nodule ≥ 10 mm). For SMICs, resection rates were en bloc 81.4 %, R0 65.1 %, and curative 30.2 %. Curative resection rate improved from 13.6 % to 47.6 % over the study period (<i>P</i> = 0.036). The reason for 83.3 % (25/30) of noncurative resections was submucosal invasion exceeding 1000 µm. For benign lesions (n = 250, 82.8 %), the R0 resection increased from 55.2 % to 84.8 % over the study period (<i>P</i> < 0.001). Recurrence rate was 4.8 %, bleeding rate 5.2 %, and perforation rate 0.8 % (all complications managed conservatively). Median follow-up was 35 months. <b>Conclusions</b> The majority of rectal LNPCPs are benign lesions. ESD offers high R0 resection and low recurrence rates but EMR may be appropriate. In lesions with a risk for SMIC, ESD should be offered to achieve R0 resection. Despite high rates of R0 resection the curative resection rate of ESD for rectal SMIC is < 50 %. Pretherapeutic lesion selection needs improvement.
PTH-133 Nutrition Training in UK Medical Undergraduate Programmes – Has The Situation Improved?
Authors: W Long, P Neild
Journal: Gut (2016)

<h3>Introduction</h3> Nutrition education in medical schools has historically been neglected and found to be inadequate.<sup>1</sup> Programmes designed to improve nutrition training have shown increased student knowledge.<sup>2,3</sup> The aim of this study was to survey current nutrition training provided by UK medical schools. <h3>Methods</h3> A 14 item questionnaire was sent to academics representing all UK medical schools on a national undergraduate nutrition education implementation group. . Data was analysed using SPSS version 21.0 and significance determined using a 2 tailed Fischer's exact test. <h3>Results</h3> The response rate was 34%(11of 32). Students' knowledge was assessed in 8 of 11 (73%) medical schools. The mean total time devoted to nutrition was 18.4 hrs (range 4 to 40+). 7/10 included all 4 core nutrition topics in their curriculum. 3/9 had a nutrition thread throughout their curriculum and 5/10 had a named nutrition lead. Only 3/9 perceived that their training was adequate. Of those 3, all cited ''increased formal teaching time devoted to nutrition' and 'better organisation of the nutrition teaching' as improvements that facilitated adequate training. Of those who reported inadequate training, 83% cited 'lack of prioritisation' and 67% cited 'unable to devote more teaching time to nutrition' and 'difficulty organising topics and teaching sessions' as hindrances towards improving training. The presence of a nutrition lead was associated with a trend to greater mean total time allocated to structured teaching (25.4 vs 16.2 hours) and greater likelihood of teaching all four core areas (5/5 vs 2/5, p = 0.08). <h3>Conclusion</h3> Indicators of good training appear to be more common in courses placing a higher priority on nutrition, including the presence of a named nutrition lead. Despite a decrease in the % of respondents reporting adequate training compared to a previous study in 20091<sup>1</sup>(33% vs 50%), indicators of good training appear to have increased. This may reflect increased awareness of the standards required as a result of the development of a standardised national nutrition curriculum, signposted in the 2009 edition of 'Tomorrow's Doctors'.<sup>4</sup> <h3>References</h3> 1 Johnston R, Neild P, Jeanes Y, Bowling T. Nutrition training in UK medical undergraduate programmes. Proceedings of the <i>Nutrition Society</i> 2009;<b>68</b>:(OCE1). 2 Maher B, Sweeney C, O'Tuathaigh C, O'Flynn S, Brown, J. Evaluation of a novel nutrition education intervention for medical students. Proceedings of the <i>Nutrition Society</i> 2013;<b>72</b>:(OCE3). 3 Taren D.Effect of an integrated nutrition curriculum on medical education, student clinical performance, and student perception of medical-nutrition training. <i>American Journal of Clinical Nutrition</i> 2001;<b>73:</b> 1107–1112 4 GMC. Tomorrow's Doctors. London 2009; http://www.aormc.uk.ore/static/documents/content/TomorrowsDoctors2009pdf. <h3>Disclosure of Interest</h3> None Declared
SP0003 Three RA Patients with Pain Catastrophizing
Authors: A. Mathiessen
Journal: Annals of the Rheumatic Diseases (2016)

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease causing pain and disability. Discordance between inflammatory activity and pain in RA has earlier been reported, and one important psychosocial factor that influences the experience of pain is <i>catastrophizing</i>. Pain catastrophizing involves both cognitive and emotional components of pain perception, and leads the patient to expect the worst. Several studies have shown that pain catastrophizing is important for the pain experience in RA, with no clear correlation to objective clinical parameters. Patients9 perspective, including pain, patient global assessment and fatigue, has increasingly been recognized as an outcome measure for therapies. Catastrophizing may therefor influence disease activity scores in RA and also measurements of response to biologic disease modifying drugs (bDMARD). Three patients with RA starting bDMARD will we presented through one-year follow-up data from the ULRABIT cohort. The patients reveal different pain catastrophizing levels during the study, and we will explore the impact of catastrophizing on subjective and composite scores, in contrast to objective inflammatory variables such as CRP, swollen joint count or ultrasound synovitis. Further, we will discuss the impact of pain catastrophizing on DAS28 remission, demonstrating the difficulties in reaching remission according to composite scores if there are increased levels of pain catastrophizing. Patient 1: high level of pain catastrophizing both at baseline and at 12 months. Patient 2: pain catastrophizer at baseline, but not at 12 months. Patient 3: neither pain catastrophizer at baseline nor at 12 months. <h3>Disclosure of Interest</h3> None declared
Altered Kinetics and Localization of MMSET Variants Suggests That RE-IIBP Overexpression Is a Unifying Event in t(4;14)(p16;q32) Multiple Myeloma.
Authors: Jonathan J. Keats, Christopher A. Maxwell, Tony Reiman, Brian J. Taylor, Michael J. Mant, Andrew J. Belch, Linda M. Pilarski
Journal: Blood (2004)
SAT0016 Role of PCR, GCKR, HNF1A, LEPR, ASCL1 and NLRP3 in Atherosclerosis in Patients with Rheumatoid Arthritis
Authors: R. Lopez-Mejías, F. Genre, S. Remuzgo-Martínez, M. Robustillo-Villarino, B. Ubilla, J. Llorca, V. Mijares, A. Corrales, C. González-Juanatey, J.A. Miranda-Filloy, T. Pina, R. Blanco, E. Vicente, J.J. Alegre-Sancho, C. Magro, E. Raya, B. Tejera-Segura, M.A. Ramírez Huaranga, C. Gόmez-Vaquero, A. Balsa, D. Pascual-Salcedo, F.J. Lόpez-Longo, P. Carreira, I. González-Άlvaro, L. Rodríguez-Rodríguez, B. Fernández-Gutiérrez, I. Ferraz-Amaro, S. Castañeda, J. Martín, M.A. González-Gay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is an autoimmune inflammatory disease associated with accelerated atherosclerosis and increased cardiovascular (CV) disease. Elevated levels of the C-reactive protein (CRP) are related to an increase risk of coronary artery disease [1] and stroke [2]. Recently, PCR, GCKR, HNF1A, LEPR, ASCL1 and NLRP3 have been associated with CRP levels in non-rheumatic population [2]. <h3>Objectives</h3> We aimed to determine the potential role of these genes in the development of CV disease and subclinical atherosclerosis in patients with RA. <h3>Methods</h3> Genotyping was performed in 2,384 Spanish RA patients by TaqMan assays. Subclinical atherosclerosis was determined by carotid ultrasonography (US) in 1,193 patients. <h3>Results</h3> No statistically significant differences were found when PCR, GCKR, HNF1A, LEPR, ASCL1 and NLRP3 were assessed according to the presence/absence of CV disease. It was also the case when patients were stratified according the presence/absence of subclinical atherosclerosis. <h3>Conclusions</h3> Our results do not confirm an association between these genes and the development of CV disease and subclinical atherosclerosis in patients with RA. <h3>References</h3> Danesh et al. N Engl J Med 2004, 350(14):1387–1397; Ridker et al. N Engl J Med 1997, 336(14):973–979; Dehghan A et al. Circulation, 123(7):731–738. <h3>Acknowledgement</h3> This study was supported by European Union FEDER funds and "Fondo de Investigaciόn Sanitaria" (grants PI12/00060 and PI15/00525) from `Instituto de Salud Carlos III" (ISCIII, Health Ministry, Spain). It was also partially supported by RETICS Programs RD12/0009 (RIER) from "Instituto de Salud Carlos III" (ISCIII, Health Ministry, Spain), and in part by grants from the European IMI BTCure Program. RL-M and BU is supported by funds from the RETICS Program (RIER) (RD12/0009/0013). FG is a recipient of a Sara Borrell postdoctoral fellowship from the "Instituto Carlos III de Salud" at the Spanish Ministry of Health (Spain) (CD15/00095). <h3>Disclosure of Interest</h3> None declared
FRI0435 About Half of The Patients with Ankylosing Spondylitis Already Have Radiographic Changes in T Spine at The Point of Diagnosis; Cross Sectional Study, by Whole Spine Ct
Authors: S.-H. Lee, J.-Y. Choi, R. Song, Y.-A. Lee, S.-J. Hong, H.-I. Yang
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ankylosing spondylitis (AS) is a chronic inflammatory disease, which destructs spine. After ivnolvement of sacroiliac joint, inflammation usually spreads from lower L spine to C spine. But it is hard to evaluate radiographic changes in T spine due to air in lung by X-ray. <h3>Objectives</h3> We performed this study to find out how many patients have radiographic changes in T spine at first visit and if bone spurs of vertebral bodies are associated with radiographic changes in facet joints in spine. <h3>Methods</h3> We enrolled the patients who were diagnosed as AS by modified NY criteria in Kyung Hee university hospital at Gangdong in Seoul, South Korea from Mar 2008 to Dec 2015. After diagnosis, we performed a whole spine CT in each patient according to the routine protocol of our clinic to evaluate the radiographic involvement of spine. Total 1,170 patients were enrolled and analyzed. We examined the presence of bone spurs in vertebral bodies (VB) and radiographic changes of facet joints in L and T spine and costovertebral joints (CVJ). <h3>Results</h3> Of the 1,170 enrolled patients. 920 were men (79%) and 85% were HLA B27 positive. Incidences of past history of peripheral arthritis and uveitis were 29.0% and 30.6%, respectively. Mean age was 33.0 ± 10.0 years and mean disease duration was 10.5 ± 9.5 years. 34.1% of patients had at least one bone spur and 26.3% had at least one lesion in facet joints in L spine. In T spine, 47. 2% of patients had already at least one bone spur, 28.2% had at least one lesion in facet joints. 32.8% had already at least one lesion in CVJs. Each radiographic change is associated with one another (p=0.00). These all radiographic changes were significantly more frequently observed in the patients with old age and long disease duration at the point of diagnosis (p=0.00). The lesion of CVJs and facet joints in T spine were observed more frequently in male than female significantly (respectively p=0.02, 0.00). 19.2% of the patients had radiographic changes in T spine without in L spine. <h3>Conclusions</h3> At the point of diagnosis, many patients already had radiographic changes in T spine. We suggest if radiographic change of T spine is included in radiographic progression score system such as mSASSS, we can more sensitively detect radiographic progression even in a short interval. <h3>Disclosure of Interest</h3> None declared
Optimization, characterization and in vitro/vivo evaluation of azilsartan nanocrystals
Authors: Jingjing Ma, Yinxian Yang, Yinghua Sun, Jin Sun
Journal: Asian Journal of Pharmaceutical Sciences (2016)

Azilsartan (AZL), a poorly soluble drug, was considered to be fit for nanocrystals to improve its solubility. Our study intended to prepare AZL nanocrystals by means of bead milling method. Eight stabilizers or their binary combination and the milling time were set to be variable factors to optimize AZL nanosuspension formulation, and six types of freeze-drying supports were investigated to reduce the aggregation of particles during the solidification. AZL nanocrystals with or without sodium deoxycholate (NaDC) as combined stabilizer with Poloxamer 188 (F68) were prepared owning mean particle sizes of about 300 nm and 460 nm. During the screening processes, the formulation containing NaDC showed a smaller particle size and better stability during lyophilization. The irregular shape and crystal form changing in AZL nanocrystals were discovered by various characterizations. And with physical mixture as reference, nanocrystals showed its improvement about in-vitro dissolution and in-vivo bioavailability. In conclusion, the nanocrystals of AZL could be prepared well in our study. Additionally, our results suggested that NaDC was an appreciated excipient on the nanocrystals platform, which can exhibit the abilities of size-reduction and stability-maintaining on freeze-drying.
Corrigendum to “Mechanically resilient, injectable, and bioadhesive supramolecular gelatin hydrogels crosslinked by weak host-guest interactions assist cell infiltration and in situ tissue regeneration” [Biomaterials 101C (2016) 217–228]
Authors: Qian Feng, Kongchang Wei, Sien Lin, Zhen Xu, Yuxin Sun, Peng Shi, Gang Li, Liming Bian
Journal: Biomaterials (2016)
Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML)
Authors: B. Douglas Smith, Andrew W. Roberts, Gail J. Roboz, Mark DeWitte, Anna Ferguson, Linda Garrett, Tania Curcio, Kaysey F. Orlowski, Sue Dasen, Debra M. Bensen-Kennedy, Roland B. Walter
Journal: Blood (2015)
Adoptive Transfer of Umbilical Cord Blood (UCB)-Derived Regulatory T Cells (Tregs) to Recipients of Nonmyeloablative Unrelated Double UCB Transplantation.
Authors: Claudio Brunstein, Keli L. Hippen, David H. McKenna, Qing Cao, Julie Curtsinger, Darin Sumstad, Bruce L. Levine, James L. Riley, Carl H. June, Jeffrey S. Miller, Bruce R. Blazar, John E. Wagner
Journal: Blood (2009)
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Authors: Marie D. Gerhard-Herman, Heather L. Gornik, Coletta Barrett, Neal R. Barshes, Matthew A. Corriere, Douglas E. Drachman, Lee A. Fleisher, Francis Gerry R. Fowkes, Naomi M. Hamburg, Scott Kinlay, Robert Lookstein, Sanjay Misra, Leila Mureebe, Jeffrey W. Olin, Rajan A.G. Patel, Judith G. Regensteiner, Andres Schanzer, Mehdi H. Shishehbor, Kerry J. Stewart, Diane Treat-Jacobson, M. Eileen Walsh
Journal: Journal of the American College of Cardiology (2017)
A Phase I Trial of Total Marrow and Lymphoid Irradiation (TMLI)-Based Transplant Conditioning in Patients (Pts) with Relapsed/Refractory Acute Leukemia
Authors: Anthony Selwyn Stein, Jeffrey Y. C. Wong, Joycelynne Palmer, Margaret O'Donnell, David S. Snyder, Ni-Chun Tsai, Pablo Miguel Parker, Ricardo Spielberger, Len Farol, Guido Marcucci, Eric Radany, Tim Schultheiss, An Liu, Ibrahim Aldoss, Stephen J. Forman
Journal: Blood (2015)
Dissemenated Intravascular Coagulation in Patients with Septic Shock: Impact of Coagulation Markers on Prediction of the Mortality
Authors: Geraldine Lavigne-Lissalde, Christophe CC Combescures, Laurent LM Muller, Christian CB Bengler, Françoise FC Casano, jean-Yves JYL Lefrant, jean-Christophe JCG Gris
Journal: Blood (2008)
Hematopoietic Stem Cell Transplantation (HSCT) for Malignancies Using Plasma Depleted Umbilical Cord Blood (UCB) That Were Not Red Blood Cell Depleted.
Authors: Lawrence Petz, Auayporn Nademanee, Joseph Rosenthal, Michael Graham, Gretchen Eames, Chatchada Karanes, Lee Lee Chan, Ah Moy Tan, Poh-Lin Tan, Brian Wang, Peggy Tseng, Tiffany Chow, Tina Wu, Tang-Her Jaing, David Gjertson, Patrick Tan, Robert Chow
Journal: Blood (2006)
Isolation and Expansion of Functional Differentiating Mesenchymal Stem Cells with a Serum Deprived Medium.
Authors: Massimo Dominici, Ingo Mueller, Luigi Cafarelli, Sandra Kordowich, Rita Sternieri, Carlotta Spano, Caterina Chiodino, Ilaria Mariotti, Istvan Petak, Edwin Horwitz, Paolo Paolucci, Pierfranco Conte
Journal: Blood (2004)
Diagnostic Reliability of Pleural Fluid Protein Estimation
Authors: R D Melsom
Journal: Journal of the Royal Society of Medicine (1979)

In a series of 86 elderly patients the measurement of pleural fluid protein was found to be of limited value in distinguishing exudates from transudates, although levels above 49 gil were all found to be exudates. However, the difference in mean pleural fluid proteins in the two groups when analysed statistically was highly significant. In addition, there was a significant difference between the means within the exudative group when analysed in groups according to aetiology. Correcting for plasma albumin values did not improve discrimination between exudates and transudates despite a significant correlation between albumin and pleural fluid protein concentration.
GPs’ antibiotic prescribing falls more than 5% in a year
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Antibiotic prescribing by GPs in England has fallen markedly in the past year, show figures released by Antibiotic Research UK, a charity created to develop new antibiotics.

The average prescribing rate has fallen by over 5% in a year, dropping from 0.63 antibiotic prescriptions per head of population in 2014-15 to 0.59 a person in 2015-16, and by 11% since its peak in 2012.

Most importantly, seasonal variation (the difference between the month with the highest number of prescriptions in a year and the month with the lowest) has halved from 68% to 31% in a year, suggesting that GPs are …
Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide
Authors: Denis Caillot, Muriel Newingerm, Margaret Macro, Brigitte Pegourie, Lionel Karlin, Francesca Gay, Claire Bories, Laurence Legros, Laurent Garderet, Souhila Ikhlef, Martine Escoffre-Barbe, Bruno Royer, Laurent Voillat, Cyrille Hulin, Anne Banos, Eric G. Voog, Anne-Marie Stoppa, Lotfi Benboubker, Eva De Jongh, Sonja Zweegman, Niels Abildgaard, Katell Le Dû, Artur J. Jurczyszyn, Philippe Moreau, Thierry Facon, Evangelos Terpos, Xavier Leleu, Catherine Vieira Dos Santos, Helene Demarquette
Journal: Blood (2014)